{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:47:34Z","timestamp":1789022854678,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T00:00:00Z","timestamp":1479945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lidamycin (LDM) is a novel member of the enediyne antibiotics identified in China with potent antitumor activity. However, it remains unclear whether LDM has potential molecular targets that may affect its antitumor activity. Enhancer of zeste homolog 2 (EZH2) functions as a histone lysine methyltransferase and mediates trimethylation on histone 3 lysine 27 (H3K27me3). High EZH2 level is found to be positively correlated with the aggressiveness, metastasis and poor prognosis of cancer. Here, we aim to study the role of EZH2 in LDM-induced senescence, as well as in the cytotoxicity of LDM in human colon cancer cells. LDM is found to be relatively more potent in inhibiting the colon cancer cells harboring high EZH2 level and induces irreversible cellular senescence at IC\n                    <jats:sub>50<\/jats:sub>\n                    dose range, as evidenced by senescence-associated\n                    <jats:italic>\u03b2<\/jats:italic>\n                    -galactosidase staining, cell cycle arrest and molecular changes of senescence regulators including p21 in HCT116 and SW620 cells. More importantly, LDM is found to markedly inhibit EZH2 expression at both protein and mRNA levels upon the induction of p21 and cellular senescence. LDM also selectively inhibits EZH2 expression as compared with other histone lysine methyltransferases. Knockdown of p21 with siRNAs abolishes LDM-induced senescence, whereas EZH2 knockdown markedly increases p21 expression and causes senescent phenotype. Enrichment of both EZH2 and H3K27me3 levels in the p21 promoter region is reduced by LDM. Moreover, EZH2 overexpression reduces cellular senescence, p21 expression and DNA damage response upon LDM exposure. LDM also demonstrates potent antitumor efficacy in xenografted animal models. Collectively, our work provides first demonstration that EZH2 may mediate, at least partially, the senescence-inducing effects of LDM by regulating p21 expression and DNA damage effect. Thus, EZH2 may serve as a potential target and biomarker to indicate the clinical efficacy of the potent enediyne antitumor drug.\n                  <\/jats:p>","DOI":"10.1038\/cddis.2016.383","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T08:51:34Z","timestamp":1479977494000},"page":"e2486-e2486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells"],"prefix":"10.1038","volume":"7","author":[{"given":"Ming-Quan","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Geng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Guang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Su","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,24]]},"reference":[{"key":"BFcddis2016383_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D . The polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343\u2013349.","journal-title":"Nature"},{"key":"BFcddis2016383_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/bjc.2011.551","volume":"106","author":"CJ Chang","year":"2012","unstructured":"Chang CJ, Hung MC . The role of EZH2 in tumour progression. Br J Cancer 2012; 106: 243\u2013247.","journal-title":"Br J Cancer"},{"key":"BFcddis2016383_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","volume":"46","author":"H Yamaguchi","year":"2014","unstructured":"Yamaguchi H, Hung MC . Regulation and role of EZH2 in cancer. Cancer Res Treat 2014; 46: 209\u2013222.","journal-title":"Cancer Res Treat"},{"key":"BFcddis2016383_CR4","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1073\/pnas.1116418109","volume":"109","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012; 109: 2989\u20132994.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2016383_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108\u2013112.","journal-title":"Nature"},{"key":"BFcddis2016383_CR6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nchembio.1084","volume":"8","author":"SK Knutson","year":"2012","unstructured":"Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890\u2013896.","journal-title":"Nat Chem Biol"},{"key":"BFcddis2016383_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/187152008783497055","volume":"8","author":"RG Shao","year":"2008","unstructured":"Shao RG, Zhen YS . Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology. Anticancer Agents Med Chem 2008; 8: 123\u2013131.","journal-title":"Anticancer Agents Med Chem"},{"key":"BFcddis2016383_CR8","doi-asserted-by":"publisher","first-page":"14975","DOI":"10.1021\/bi972101o","volume":"36","author":"Y Xu","year":"1997","unstructured":"Xu Y, Xi Z, Zhen Y, Goldberg IH . Mechanism of formation of novel covalent drug\u00b7DNA interstrand cross-links and monoadducts by enediyne antitumor antibiotics. Biochemistry 1997; 36: 14975\u201314984.","journal-title":"Biochemistry"},{"key":"BFcddis2016383_CR9","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1021\/bi001668t","volume":"40","author":"MM McHugh","year":"2001","unstructured":"McHugh MM, Yin X, Kuo SR, Liu JS, Melendy T, Beerman TA . The cellular response to DNA damage induced by the enediynes C-1027 and neocarzinostatin includes hyperphosphorylation and increased nuclear retention of replication protein a (RPA) and trans inhibition of DNA replication. Biochemistry 2001; 40: 4792\u20134799.","journal-title":"Biochemistry"},{"key":"BFcddis2016383_CR10","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-09-2699","volume":"16","author":"XF Guo","year":"2010","unstructured":"Guo XF, Zhu XF, Shang Y, Zhang SH, Zhen YS . A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity. Clin Cancer Res 2010; 16: 2085\u20132094.","journal-title":"Clin Cancer Res"},{"key":"BFcddis2016383_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0006-2952(03)00117-5","volume":"65","author":"Z Wang","year":"2003","unstructured":"Wang Z, He Q, Liang Y, Wang D, Li YY, Li D . Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells. Biochem Pharmacol 2003; 65: 1767\u20131775.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2016383_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.4161\/cbt.6.6.4193","volume":"6","author":"L Chen","year":"2007","unstructured":"Chen L, Jiang J, Cheng C, Yang A, He Q, Li D et al. P53 dependent and independent apoptosis induced by lidamycin in human colorectal cancer cells. Cancer Biol Ther 2007; 6: 965\u2013973.","journal-title":"Cancer Biol Ther"},{"key":"BFcddis2016383_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mc.22069","volume":"54","author":"Y Chen","year":"2015","unstructured":"Chen Y, Yu D, Zhang C, Shang B, He H, Chen J et al. Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta\/beta-catenin pathway. Mol Carcinog 2015; 54: 1\u20138.","journal-title":"Mol Carcinog"},{"key":"BFcddis2016383_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1756-8935-2-16","volume":"2","author":"S Kheradmand Kia","year":"2009","unstructured":"Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E, Pourfarzad F, von Lindern M, Verrijzer CP . EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenet Chromatin 2009; 2: 16.","journal-title":"Epigenet Chromatin"},{"key":"BFcddis2016383_CR15","doi-asserted-by":"publisher","first-page":"33061","DOI":"10.1074\/jbc.M111.257667","volume":"286","author":"A Tzatsos","year":"2011","unstructured":"Tzatsos A, Paskaleva P, Lymperi S, Contino G, Stoykova S, Chen Z et al. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem 2011; 286: 33061\u201333069.","journal-title":"J Biol Chem"},{"key":"BFcddis2016383_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1158\/1541-7786.MCR-10-0511","volume":"9","author":"T Fan","year":"2011","unstructured":"Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21\/CDKN1A expression. Mol Cancer Res 2011; 9: 418\u2013429.","journal-title":"Mol Cancer Res"},{"key":"BFcddis2016383_CR17","first-page":"189","volume":"20","author":"RJ Gao","year":"2007","unstructured":"Gao RJ, Liang YX, Li DD, Zhang HY, Zhen YS . Effect of lidamycin on telomerase activity in human hepatoma BEL-7402 cells. Biomed Environ Sci 2007; 20: 189\u2013197.","journal-title":"Biomed Environ Sci"},{"key":"BFcddis2016383_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.4161\/cbt.8.16.8955","volume":"8","author":"Y Pan","year":"2009","unstructured":"Pan Y, Ren KH, He HW, Shao RG . Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2\/M checkpoint and induction of apoptosis. Cancer Biol Ther 2009; 8: 1559\u20131566.","journal-title":"Cancer Biol Ther"},{"key":"BFcddis2016383_CR19","first-page":"597","volume":"17","author":"X Liu","year":"2007","unstructured":"Liu X, Bian C, Ren K, Jin H, Li B, Shao RG . Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway. Oncol Rep 2007; 17: 597\u2013603.","journal-title":"Oncol Rep"},{"key":"BFcddis2016383_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-59745-361-5_3","volume":"371","author":"K Itahana","year":"2007","unstructured":"Itahana K, Campisi J, Dimri GP . Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol Biol 2007; 371: 21\u201331.","journal-title":"Methods Mol Biol"},{"key":"BFcddis2016383_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi J . Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75: 685\u2013705.","journal-title":"Annu Rev Physiol"},{"key":"BFcddis2016383_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ccr.2005.05.025","volume":"7","author":"GP Dimri","year":"2005","unstructured":"Dimri GP . What has senescence got to do with cancer? Cancer Cell 2005; 7: 505\u2013512.","journal-title":"Cancer Cell"},{"key":"BFcddis2016383_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.surg.2013.06.041","volume":"154","author":"RB Batchu","year":"2013","unstructured":"Batchu RB, Qazi AM, Gruzdyn OV, Semaan A, Seward SM, Chamala S et al. EZH2-shRNA-mediated upregulation of p21waf1\/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma. Surgery 2013; 154: 739\u2013746.","journal-title":"Surgery"},{"key":"BFcddis2016383_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.canlet.2013.04.012","volume":"336","author":"S Seward","year":"2013","unstructured":"Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, Bryant CC et al. EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1\/cip1) and by inhibiting mutant p53. Cancer Lett 2013; 336: 53\u201360.","journal-title":"Cancer Lett"},{"key":"BFcddis2016383_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","volume":"32","author":"R Margueron","year":"2008","unstructured":"Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32: 503\u2013518.","journal-title":"Mol Cell"},{"key":"BFcddis2016383_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis CD, Jenuwein T . The molecular hallmarks of epigenetic control. Nat Rev Genet 2016; 17: 487\u2013500.","journal-title":"Nat Rev Genet"},{"key":"BFcddis2016383_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3322\/caac.21220","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Desantis C, Jemal A . Colorectal cancer statistics 2014 CA Cancer J Clin 2014; 64: 104\u2013117.","journal-title":"CA Cancer J Clin"},{"key":"BFcddis2016383_CR28","first-page":"1817","volume":"7","author":"L Li","year":"2014","unstructured":"Li L, Ma BB . Colorectal cancer in Chinese patients: current and emerging treatment options. Onco Targets Ther 2014; 7: 1817\u20131828.","journal-title":"Onco Targets Ther"},{"key":"BFcddis2016383_CR29","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.3748\/wjg.v10.i18.2632","volume":"10","author":"YX Liang","year":"2004","unstructured":"Liang YX, Zhang W, Li DD, Liu HT, Gao P, Sun YN et al. Mitotic cell death in BEL-7402 cells induced by enediyne antibiotic lidamycin is associated with centrosome overduplication. World J Gastroenterol 2004; 10: 2632\u20132636.","journal-title":"World J Gastroenterol"},{"key":"BFcddis2016383_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0895-3988(09)60052-0","volume":"22","author":"AJ Yang","year":"2009","unstructured":"Yang AJ, Shi WW, Li Y, Wang Z, Shao RG, Li DD et al. Role of prosurvival molecules in the action of lidamycin toward human tumor cells. Biomed Environ Sci 2009; 22: 244\u2013252.","journal-title":"Biomed Environ Sci"},{"key":"BFcddis2016383_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1158\/0008-5472.CAN-10-1850","volume":"71","author":"J Lu","year":"2011","unstructured":"Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71: 225\u2013233.","journal-title":"Cancer Res"},{"key":"BFcddis2016383_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cellsig.2016.02.004","volume":"28","author":"S Sun","year":"2016","unstructured":"Sun S, Yu F, Zhang L, Zhou X . EZH2, an on-off valve in signal network of tumor cells. Cell Signal 2016; 28: 481\u2013487.","journal-title":"Cell Signal"},{"key":"BFcddis2016383_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1089\/scd.2012.0172","volume":"22","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, He L, Wan Y, Song J . H3K9me-enhanced DNA hypermethylation of the p16INK4a gene: an epigenetic signature for spontaneous transformation of rat mesenchymal stem cells. Stem Cells Dev 2013; 22: 256\u2013267.","journal-title":"Stem Cells Dev"},{"key":"BFcddis2016383_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/dna.2014.2340","volume":"33","author":"J Bai","year":"2014","unstructured":"Bai J, Chen J, Ma M, Cai M, Xu F, Wang G et al. Inhibiting enhancer of zeste homolog 2 promotes cellular senescence in gastric cancer cells SGC-7901 by activation of p21 and p16. DNA Cell Biol 2014; 33: 337\u2013344.","journal-title":"DNA Cell Biol"},{"key":"BFcddis2016383_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.apsb.2015.01.011","volume":"5","author":"M Sha","year":"2015","unstructured":"Sha M, Mao G, Wang G, Chen Y, Wu X, Wang Z . DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis. Acta Pharmaceutica Sinica B 2015; 5: 188\u2013193.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"BFcddis2016383_CR36","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"AJ Levine","year":"2009","unstructured":"Levine AJ, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749\u2013758.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2016383_CR37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871\u2013874.","journal-title":"Nature"},{"key":"BFcddis2016383_CR38","doi-asserted-by":"publisher","first-page":"e19503","DOI":"10.1371\/journal.pone.0019503","volume":"6","author":"AY So","year":"2011","unstructured":"So AY, Jung JW, Lee S, Kim HS, Kang KS . DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PloS One 2011; 6: e19503.","journal-title":"PloS One"},{"key":"BFcddis2016383_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/ng1068","volume":"33","author":"M-F Robert","year":"2003","unstructured":"Robert M-F, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003; 33: 61\u201365.","journal-title":"Nat Genet"},{"key":"BFcddis2016383_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.molcel.2009.09.021","volume":"36","author":"PD Adams","year":"2009","unstructured":"Adams PD . Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell 2009; 36: 2\u201314.","journal-title":"Mol Cell"},{"key":"BFcddis2016383_CR41","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.4161\/cc.25795","volume":"12","author":"S Campbell","year":"2013","unstructured":"Campbell S, Ismail IH, Young LC, Poirier GG, Hendzel MJ . Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle 2013; 12: 2675\u20132683.","journal-title":"Cell Cycle"},{"key":"BFcddis2016383_CR42","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/cdd.2011.48","volume":"18","author":"Z Wu","year":"2011","unstructured":"Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ et al. Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ 2011; 18: 1771\u20131779.","journal-title":"Cell Death Differ"},{"key":"BFcddis2016383_CR43","doi-asserted-by":"crossref","unstructured":"de Vries NA, Hulsman D, Akhtar W, de Jong J, Miles DC, Blom M et al. Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression. Cell Rep 2015.","DOI":"10.1016\/j.celrep.2014.12.028"},{"key":"BFcddis2016383_CR44","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/onc.2008.433","volume":"28","author":"ME Gonzalez","year":"2009","unstructured":"Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28: 843\u2013853.","journal-title":"Oncogene"},{"key":"BFcddis2016383_CR45","doi-asserted-by":"crossref","unstructured":"Huang Y, Wang X, Niu X, Wang X, Jiang R, Xu T et al. EZH2 suppresses the nucleotide excision repair in nasopharyngeal carcinoma by silencing XPA gene. Mol Carcinog 2016.","DOI":"10.1002\/mc.22507"},{"key":"BFcddis2016383_CR46","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1158\/0008-5472.CAN-08-4671","volume":"69","author":"L Jia","year":"2009","unstructured":"Jia L, Soengas MS, Sun Y . ROC1\/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res 2009; 69: 4974\u20134982.","journal-title":"Cancer Res"},{"key":"BFcddis2016383_CR47","doi-asserted-by":"publisher","first-page":"21183","DOI":"10.1074\/jbc.M311912200","volume":"279","author":"PS Kho","year":"2004","unstructured":"Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH et al. p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 2004; 279: 21183\u201321192.","journal-title":"J Biol Chem"},{"key":"BFcddis2016383_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1023\/A:1006326203858","volume":"17","author":"RM Hoffman","year":"1999","unstructured":"Hoffman RM . Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17: 343\u2013359.","journal-title":"Invest New Drugs"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2016383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2016383","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2016383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T04:10:33Z","timestamp":1672805433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2016383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,24]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"alternative-id":["BFcddis2016383"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2016.383","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,24]]},"assertion":[{"value":"17 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}